Insulet (PODD) Stock Rating Lowered by BidaskClub

BidaskClub lowered shares of Insulet (NASDAQ:PODD) from a hold rating to a sell rating in a research report report published on Thursday.

PODD has been the subject of several other reports. Jefferies Group lifted their price objective on shares of Insulet from $58.00 to $67.00 and gave the stock a buy rating in a research note on Friday, November 3rd. Canaccord Genuity raised shares of Insulet from a hold rating to a buy rating and lifted their price objective for the stock from $50.00 to $65.00 in a research note on Wednesday, November 1st. Raymond James Financial raised shares of Insulet from a market perform rating to an outperform rating and set a $80.00 price objective for the company in a research note on Monday, January 8th. Zacks Investment Research lowered shares of Insulet from a buy rating to a hold rating in a research note on Saturday, November 11th. Finally, UBS Group raised shares of Insulet from a market perform rating to an outperform rating in a research note on Monday, January 8th. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and twelve have given a buy rating to the stock. The stock has a consensus rating of Buy and an average price target of $62.53.

Insulet (PODD) opened at $75.18 on Thursday. Insulet has a fifty-two week low of $38.43 and a fifty-two week high of $78.65. The company has a debt-to-equity ratio of 4.65, a current ratio of 4.88 and a quick ratio of 4.42. The firm has a market cap of $4,370.00, a price-to-earnings ratio of -150.36 and a beta of 1.58.

Insulet (NASDAQ:PODD) last posted its earnings results on Thursday, November 2nd. The medical instruments supplier reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.06. Insulet had a negative net margin of 6.66% and a negative return on equity of 43.85%. The firm had revenue of $121.80 million during the quarter, compared to analyst estimates of $114.02 million. During the same period last year, the firm posted ($0.05) earnings per share. Insulet’s revenue for the quarter was up 28.4% compared to the same quarter last year. research analysts predict that Insulet will post -0.43 EPS for the current year.

In other Insulet news, Director James C. Mullen bought 2,500 shares of the firm’s stock in a transaction dated Monday, November 13th. The stock was acquired at an average cost of $67.45 per share, for a total transaction of $168,625.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 1.90% of the stock is currently owned by company insiders.

Several large investors have recently added to or reduced their stakes in the company. The Manufacturers Life Insurance Company lifted its position in shares of Insulet by 0.4% during the second quarter. The Manufacturers Life Insurance Company now owns 44,746 shares of the medical instruments supplier’s stock worth $2,296,000 after purchasing an additional 198 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Insulet by 11.4% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,302 shares of the medical instruments supplier’s stock worth $118,000 after purchasing an additional 235 shares during the last quarter. Legal & General Group Plc lifted its position in shares of Insulet by 1.9% during the second quarter. Legal & General Group Plc now owns 20,233 shares of the medical instruments supplier’s stock worth $1,034,000 after purchasing an additional 376 shares during the last quarter. Amalgamated Bank lifted its position in shares of Insulet by 5.7% during the second quarter. Amalgamated Bank now owns 7,476 shares of the medical instruments supplier’s stock worth $384,000 after purchasing an additional 406 shares during the last quarter. Finally, TIAA CREF Investment Management LLC lifted its position in shares of Insulet by 0.6% during the second quarter. TIAA CREF Investment Management LLC now owns 156,898 shares of the medical instruments supplier’s stock worth $8,050,000 after purchasing an additional 863 shares during the last quarter.

TRADEMARK VIOLATION NOTICE: “Insulet (PODD) Stock Rating Lowered by BidaskClub” was originally reported by TrueBlueTribune and is owned by of TrueBlueTribune. If you are reading this story on another website, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this story can be read at https://www.truebluetribune.com/2018/01/22/insulet-podd-stock-rating-lowered-by-bidaskclub.html.

About Insulet

Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).

Analyst Recommendations for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply